当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Rinonapoli G, Ceccarini P, Altissimi M and Caraffa A
Diabetes is the leading cause of non-traumatic amputation in the world. Patients with diabetes have a 10-fold increased risk for lower extremity amputation compared with those who do not have diabetes. Amputees with diabetes are more likely to be severely disabled, to experience their initial amputation at a younger age, progress to higher-level amputations, and die at a younger age compared with patients without diabetes. Indications for amputation are chronic lower limb ulcers, infected or not infected, due to peripheral neuropathy, vascular disease or deformity of the feet. Foot ulcer precedes amputations in 84% of the cases. Amputation in diabetes is not a riskless treatment. The 5-year relative mortality rate is 48% after major limb loss. After a major limb loss, there is a 50% probability of developing a serious lesion on the contralateral limb within 2 years. In the present review and clinical appraisal, indications for determination of the level of amputation, the possible consequences of a specific amputation on stance, deambulation, necessity of using a specific footwear or prosthesis, technical problems and complications are discussed.